Acute Pharmacokinetic-pharmacodynamic Change of Rocuronium After Reperfusion of Renal Graft

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Jul 8, 2016

Keywords

ClinConnect Summary

This clinical trial is studying how kidney transplantation affects the way a muscle relaxant called rocuronium works in the body. When a new kidney is reattached during surgery, it can cause changes in how this medication is processed and eliminated from the body. The main goal of the study is to better understand these changes so that doctors can give the right amount of rocuronium during the transplant, ensuring patients have stable muscle relaxation and recover quickly after the procedure.

To participate in this trial, you need to be scheduled for a living donor kidney transplant and have end-stage kidney disease, which means your kidneys are not working properly. You should also be in a healthy weight range. If you have a condition that affects your muscles, you may not be eligible. If you choose to participate, you can expect that the study will involve careful monitoring during your surgery to help improve how medications are used in future kidney transplants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients scheduled for elective living donor kidney transplantation
• • end stage renal disease with oliguria or anuria
• • normal BMI (BMI 18.5 \~ 25)
• • obtained informed consent
• Exclusion Criteria:
• • patient with underlying neuromuscular disease